Why the Breast Cancer Screening Age Moved to Forty

In April 2024, the US Preventive Services Task Force finalized a recommendation that women at average risk begin biennial screening mammography at age 40, and it attached a Grade B to that advice. A Grade B is a specific claim in the Task Force's vocabulary: moderate certainty that the service carries a moderate net benefit. The grade did not come from one decisive trial. It came from pairing the direct trial evidence that exists with six independent simulation models that estimated what starting earlier would gain and what it would cost, counted per 1000 women over a lifetime. Reading the guideline as a worked example of how a grade is built is more instructive than reading it as instructions.

This article explains that construction. It is educational and not medical advice; decisions about your own screening belong with your clinician.

What actually changed in 2024

The headline shift is the starting age. The 2016 version of this recommendation had told women in their forties that the decision to screen was an individual one, a Grade C, and reserved its Grade B for routine screening from 50 to 74. The 2024 statement extends the Grade B down to age 40 and applies it uniformly across the 40-to-74 range. The interval stays biennial, meaning every two years, not annual.

Two observations pushed the Task Force to reopen the question. Breast cancer incidence has been rising among women in their forties, and Black women continue to die of breast cancer at substantially higher rates than white women despite similar screening participation. Neither of those facts is itself a reason to screen earlier. They are reasons to re-run the analysis and ask whether the balance of benefit and harm has moved.

Why trials alone could not settle it

The randomized trials of mammography were mostly designed decades ago, with screening intervals, imaging technology, and treatment regimens that no longer match current practice. They can establish that screening reduces breast cancer mortality, but they cannot cleanly answer a narrow contemporary question like biennial starting at 40 versus biennial starting at 50, using today's digital mammography and today's therapy. No trial was built to isolate that comparison.

This is a common situation in prevention. The clinical question outruns the trial evidence. When that happens, the Task Force commissions decision modeling to interpolate between what the trials show and what the current decision requires. The models do not invent evidence. They take trial-derived and registry-derived inputs about tumor growth, test sensitivity, and treatment effectiveness, then simulate populations under competing screening schedules.

The role of the six models

For this update, the Cancer Intervention and Surveillance Modeling Network, known as CISNET, ran six independently developed models of breast cancer natural history and screening. Using six rather than one is a deliberate hedge against the assumptions baked into any single model. Where the models agree, the conclusion is more robust; where they diverge, that disagreement is itself information about uncertainty.

The central estimate is worth stating precisely. Moving biennial screening from a start age of 50 down to 40 was projected to avert roughly 1.3 additional breast cancer deaths per 1000 women screened. The same move was projected to add about 503 additional false-positive recalls, 65 additional benign biopsies, and 2 additional overdiagnosed cancers per 1000 women. Those are the numbers a grade has to reconcile: a real mortality gain, set against a larger volume of false alarms and a small amount of overdiagnosis, meaning cancers found that would never have caused harm.

Why biennial, not annual

The same modeling framework is why the interval stayed at two years. Annual screening catches marginally more cancers earlier, but the models consistently found that the extra false positives, biopsies, and overdiagnosis it generates outweigh that marginal gain for average-risk women. Biennial screening sat at a more favorable point on the benefit-to-harm curve. The interval is not a compromise or a cost-saving default. It is where the modeled trade-off lands.

What the grade does and does not say

A Grade B is a statement about net benefit at the population level, under stated assumptions, with moderate certainty. It is not a promise about any single person, and it does not claim the evidence is airtight. The Task Force was explicit about where the evidence runs out. For women 75 and older it issued an I statement, meaning the evidence is insufficient to weigh benefits against harms. For supplemental ultrasound or MRI in women with dense breasts, it also issued an I statement, despite dense tissue being both a risk factor and a reason mammograms miss cancers. An I statement is not a recommendation against; it is an honest declaration that the analysis cannot yet support a call.

That candor is the part worth carrying away. A well-built guideline reports its own boundaries. It tells you the size of the benefit, the size of the harms, the certainty attached, and the questions it could not answer. The move to 40 reads very differently once you see it as the output of that accounting rather than a slogan about when to start.